Speaker Name: Dr. Deepak Bhatt, Director, Mount Sinai Fuster Heart Hospital, New York, United States.

Explore this expert session to:

• Understand the changing pattern of CV mortality in T2DM, with HF and sudden cardiac death now exceeding MI, as seen in SAVOR-TIMI 53.
• Review EMPA-REG OUTCOME, DAPA-HF, and EMPEROR trials establishing SGLT2 inhibitors for reducing CV death and HF hospitalization.
• Gain insight into early in-hospital SGLT2 inhibitor initiation after stabilization based on SOLOIST-WHF and EMPULSE.
• Evaluate SCORED, SELECT, and STEP-HFpEF study findings on sotagliflozin and GLP-1 RAs in T2DM, CKD, obesity, and HFpEF.
• Apply current ESC and NLA guideline recommendations for one-time Lp(a) testing and intensified ASCVD risk reduction when elevated.